ArticleTranslational cancer research2025
Examining the effectiveness of follow-up chemotherapy in large cell neuroendocrine carcinoma: special emphasis on stage T1-2N0M0 according to 9
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Large cell neuroendocrine carcinoma (LCNEC) accounts for approximately 3% of lung cancers and carries a poor prognosis. For early-stage, node-negative disease classified as T1-2N0M0 by the 9 Methods: We sourced data of patients who were diagnosed with LCNEC at the T1-2N0M0 stage and had undergone surgery, focusing on the time frame from the start of 2004 to the end of 2015, using the Surveillance, Epidemiology, and End Results (SEER) database as our resource. In order to comprehensively evaluate the cancer-specific survival (CSS) and overall survival (OS) across different groups, we implemented a multi-faceted statistical approach, encompassing subgroup analyses, propensity score matching (PSM) techniques, and Kaplan-Meier (K-M) survival curves. Additionally, we employed the Cox Proportional-Hazards model to pinpoint standalone predictors of outcomes in LCNEC staged as T1-2N0M0. Results: Of the 582 T1-2N0M0 LCNEC patients studied, 473 (81%) patients underwent surgery alone. Before and after applying propensity score adjustments, we found no notable variance in OS and CSS when comparing the surgery-only cohort to the group that received adjuvant chemotherapy. Exploratory subgroup analyses suggested potential heterogeneity in treatment associations, though biological plausibility was uncertain. Cox regression identified middle tumor location, segmentectomy, age ≥65 years, and zero regional nodes examined as independent prognostic factors (P<0.05). Conclusions: According to the 9
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.